Bruker Corporation $BRKR Stock Holdings Lessened by Natixis

Natixis cut its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 81.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 71,032 shares of the medical research company’s stock after selling 314,539 shares during the quarter. Natixis’ holdings in Bruker were worth $2,927,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Nisa Investment Advisors LLC lifted its holdings in shares of Bruker by 377.5% during the second quarter. Nisa Investment Advisors LLC now owns 616 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 487 shares during the last quarter. Huntington National Bank raised its holdings in Bruker by 750.0% during the 2nd quarter. Huntington National Bank now owns 731 shares of the medical research company’s stock worth $30,000 after buying an additional 645 shares during the period. Spire Wealth Management purchased a new stake in Bruker during the second quarter valued at about $32,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of Bruker by 1,354.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock worth $33,000 after buying an additional 745 shares during the period. Finally, Parallel Advisors LLC increased its position in shares of Bruker by 63.0% in the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock worth $37,000 after acquiring an additional 347 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Stock Up 3.4%

BRKR stock opened at $46.92 on Thursday. The company has a 50 day moving average of $41.28 and a two-hundred day moving average of $38.19. The company has a market cap of $7.13 billion, a price-to-earnings ratio of -293.25, a PEG ratio of 6.68 and a beta of 1.17. Bruker Corporation has a 12-month low of $28.53 and a 12-month high of $64.64. The company has a quick ratio of 0.91, a current ratio of 1.85 and a debt-to-equity ratio of 0.81.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a positive return on equity of 15.45% and a negative net margin of 0.61%.The firm had revenue of $860.50 million during the quarter, compared to analysts’ expectations of $847.40 million. During the same quarter last year, the firm earned $0.60 earnings per share. The business’s revenue for the quarter was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. On average, equities analysts anticipate that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a $0.05 dividend. The ex-dividend date of this dividend is Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Bruker’s payout ratio is presently -125.00%.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Wells Fargo & Company reduced their price target on shares of Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. TD Cowen boosted their target price on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday, November 4th. Rothschild & Co Redburn started coverage on Bruker in a report on Thursday, November 20th. They issued a “buy” rating and a $60.00 target price for the company. Cowen reaffirmed a “hold” rating on shares of Bruker in a research report on Tuesday, November 4th. Finally, Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price target on the stock in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus target price of $50.62.

Insider Buying and Selling

In related news, Director John A. Ornell sold 6,233 shares of the stock in a transaction that occurred on Thursday, November 6th. The stock was sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director owned 35,212 shares in the company, valued at approximately $1,373,268. This represents a 15.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Cynthia M. Friend sold 3,535 shares of Bruker stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total transaction of $114,003.75. Following the completion of the sale, the director owned 18,016 shares of the company’s stock, valued at $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 27.30% of the company’s stock.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.